Home/Pipeline/EXO‑CD24

EXO‑CD24

Acute Respiratory Distress Syndrome (ARDS)

Phase 2Active

Key Facts

Indication
Acute Respiratory Distress Syndrome (ARDS)
Phase
Phase 2
Status
Active
Company

About Nano24med

Exosome‑delivered CD24 immunomodulator for ARDS and cytokine‑storm diseases.

View full company profile

About Nano24med

Exosome‑delivered CD24 immunomodulator for ARDS and cytokine‑storm diseases.

View full company profile

Other Acute Respiratory Distress Syndrome (ARDS) Drugs

DrugCompanyPhase
MultiStemAthersysPhase 3
BXT-25BioXyTranPreclinical
Bioengineered Surfactant ProgramBioSuperiorPre-clinical
FX06F4 PharmaPhase 1/2
AVM0703AVM BiotechnologyPre-clinical / Research
ACE2v2-FcCyrus BiotechnologyPreclinical
GEn-1124GEn1E LifesciencesPhase 2
AZM-152Azome TherapeuticsPre-clinical
Zelpultide AlfaAirway TherapeuticsPre-clinical/Research
ALT-100 mAbAqualung TherapeuticsPhase 2a
RP-323PhorMedPhase 2
Research Grant: Effect of volatile sedation on spontaneous breathing in ARDSSedana MedicalInvestigator-Initiated Trial